+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


2021 Global Drug Bioavailability Enhancement Summit (San Diego, CA, United States - March 2-4, 2021)

  • ID: 4991343
  • Conference
  • Location: San Diego, CA, United States
  • 3 Days
  • Curtis & Coulter
  • Conference Dates: March 2-4, 2021
until Dec 03rd 2020
1 of 3

Gather insights into the latest technologies and methods of new drug formulation and bioavailability enhancement strategies.

It’s no lie the drug development model is in need of a drastic shakeup. With lengthy and costly approval processes, generic incursion, rising development costs and the need for novel adherence strategies, pharma and biotech, now more than ever need to initiate innovative formulation, delivery and development approaches in order to improve bioavailability and therapeutic performance.

We’re here to help. The 2021 Global Drug Bioavailability Enhancement Summit will connect industry leaders from both small molecule and biologics areas to address challenges at the interface between drug discovery and preclinical/clinical development. 2021’s Summit will share cutting edge research on the development, characterization and manufacture of formulations that span multiple modalities. Hear from 30+ senior drug bioavailability pioneers and network with 120+ senior drug development innovators and walk away with over 2 years of new drug formulation and bioavailability enhancement approaches strategies in just 2 days!

Are you looking to improve drug performance, bioavailability and patient adherence? Would you like to reduce dosage, cost and time-to-market? Get involved today at the 2021 Summit and dramatically increase the performance and activity of your current and future drug products.

  • 30+ Industry-led Speakers
  • 120+ Senior Participants
  • 14+ Networking Hours
  • 16 Tech Exhibitors

You Will Learn

  • Precision medicine & healthcare delivery
  • Rationale formulation design for poorly soluble compounds
  • In-vivo - in-vitro correlation
  • Solution behavior of amorphous solid dispersions
  • Nanosuspension for improving the bioavailability
  • Early formulation screening in drug discovery
  • 3D printing for biopharmaceuticals
  • Enhancing patient adherence via drug delivery
  • Innovative strategies around drug/device combinations
Note: Product cover images may vary from those shown
2 of 3


3 of 3

Rakesh Dixit, PhD
President & CEO

Ildiko Terebesi, PhD
Head, Early Formulation Development

Wei Zhu, PhD
Senior Scientist, Biopharmaceutics & Speciality Dosage Forms
Merck & Co.

Rick Panicucci, PhD
Senior Vice President, CMC
QED Therapeutics

Dedong Wu, PhD
Senior Scientist, Pharmaceutical Science

Doug Nesta, PhD
Senior Director, Biopharmaceutical Product Sciences

Dina Zhang, PhD
Senior Research Fellow
Merck & Co.

John Morrison, PhD
Senior Research Investigator
Bristol Myers Squibb.

Bob Prud'Homme, PhD
Professor and Director Program in Engr. Biology
Princeton University

Saileta Prabhu, PhD
Senior Director/Head, PKPD

Indrajit Ghosh, PhD
Senior Principal Scientist, Pharmaceutical Science and Technology
Celgene Corporation

Phillip Snyder, PhD
Associate Director, Preclinical and Pharmaceutical Sciences
Vertex Pharmaceuticals

Note: Product cover images may vary from those shown
4 of 3


San Diego, CA
United States

Venue to be announced shortly.

Note: Product cover images may vary from those shown